Amedisys Inc (AMED) Insider David L. Kemmerly Sells 3,375 Shares of Stock

Share on StockTwits

Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 3,375 shares of Amedisys stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $117.44, for a total transaction of $396,360.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

David L. Kemmerly also recently made the following trade(s):

  • On Friday, November 9th, David L. Kemmerly sold 6,500 shares of Amedisys stock. The stock was sold at an average price of $118.87, for a total transaction of $772,655.00.

NASDAQ AMED traded up $1.46 on Friday, reaching $120.50. 476,741 shares of the company’s stock traded hands, compared to its average volume of 654,049. The company has a market capitalization of $3.77 billion, a PE ratio of 54.52, a P/E/G ratio of 1.76 and a beta of 1.22. Amedisys Inc has a fifty-two week low of $49.80 and a fifty-two week high of $127.38. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06.

Amedisys (NASDAQ:AMED) last posted its earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. The company had revenue of $417.34 million during the quarter, compared to the consensus estimate of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm posted $0.56 earnings per share. Research analysts expect that Amedisys Inc will post 3.58 earnings per share for the current year.

AMED has been the subject of several research reports. BidaskClub upgraded shares of Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Craig Hallum downgraded shares of Amedisys from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $116.00 to $104.00 in a research note on Friday, October 26th. Canaccord Genuity initiated coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 price objective for the company. SunTrust Banks lifted their price objective on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Finally, Benchmark upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a research note on Tuesday, October 30th. Five research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Amedisys currently has a consensus rating of “Buy” and a consensus price target of $105.50.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Amedisys by 7.5% during the second quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock valued at $459,945,000 after purchasing an additional 377,153 shares during the period. JPMorgan Chase & Co. lifted its position in Amedisys by 14.6% during the third quarter. JPMorgan Chase & Co. now owns 934,137 shares of the health services provider’s stock valued at $116,731,000 after purchasing an additional 118,936 shares during the period. Acadian Asset Management LLC lifted its position in Amedisys by 218.9% during the third quarter. Acadian Asset Management LLC now owns 609,586 shares of the health services provider’s stock valued at $76,177,000 after purchasing an additional 418,424 shares during the period. Rothschild Asset Management Inc. lifted its position in Amedisys by 0.3% during the second quarter. Rothschild Asset Management Inc. now owns 447,262 shares of the health services provider’s stock valued at $38,223,000 after purchasing an additional 1,278 shares during the period. Finally, Alliancebernstein L.P. lifted its position in Amedisys by 141.4% during the third quarter. Alliancebernstein L.P. now owns 396,533 shares of the health services provider’s stock valued at $49,551,000 after purchasing an additional 232,255 shares during the period. Institutional investors own 93.58% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://baseballnewssource.com/2018/11/10/amedisys-inc-amed-insider-david-l-kemmerly-sells-3375-shares-of-stock/2971845.html.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Read More: Reverse Stock Split

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.